GIS Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Rewards
Risk Analysis
Gilead Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$66.68 |
52 Week High | US$80.00 |
52 Week Low | US$57.29 |
Beta | 0.20 |
11 Month Change | 1.26% |
3 Month Change | 8.72% |
1 Year Change | -5.36% |
33 Year Change | 13.29% |
5 Year Change | 11.06% |
Change since IPO | 4,636.43% |
Recent News & Updates
Recent updates
Shareholder Returns
GIS | DE Biotechs | DE Market | |
---|---|---|---|
7D | -2.9% | -1.0% | -0.7% |
1Y | -5.4% | -19.5% | 1.4% |
Return vs Industry: GIS exceeded the German Biotechs industry which returned -19.5% over the past year.
Return vs Market: GIS underperformed the German Market which returned 1.4% over the past year.
Price Volatility
GIS volatility | |
---|---|
GIS Average Weekly Movement | 3.6% |
Biotechs Industry Average Movement | 6.1% |
Market Average Movement | 4.6% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GIS has not had significant price volatility in the past 3 months.
Volatility Over Time: GIS's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
GIS fundamental statistics | |
---|---|
Market cap | €84.39b |
Earnings (TTM) | €446.98m |
Revenue (TTM) | €25.30b |
188.8x
P/E Ratio3.3x
P/S RatioIs GIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GIS income statement (TTM) | |
---|---|
Revenue | US$27.45b |
Cost of Revenue | US$6.17b |
Gross Profit | US$21.28b |
Other Expenses | US$20.80b |
Earnings | US$485.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | 0.39 |
Gross Margin | 77.52% |
Net Profit Margin | 1.77% |
Debt/Equity Ratio | 144.3% |
How did GIS perform over the long term?
See historical performance and comparison